Abstract:e24134 Background: Most advanced non-small cell lung cancer (NSCLC) cases do not respond to anti-PD1 therapy, because most NSCLC avoids immune-recognition in the 1st place, e.g, by epigenetic suppression of neo-antigen expression by DNA methyltransferase (DNMT1). DNMT1 is depleted by the clinical drugs decitabine (Dec) and 5-Azacytidine (5Aza), however, Dec/5Aza have trivial distribution into solid tissues because of rapid deamination by cytidine deaminase (CDA) in vivo, undermining application to treat NSCLC. We therefore combined a CDA inhibitor tetrahydrouridine (THU) with Dec/5Aza. Methods: Mice were inoculated with LL3-luc cells via tail vein (syngeneic) or patient tumor and PBMC via SC and tail vein (humanized PDX). Treatment with PBS (veh), THU-Dec/5Aza (10/0.1/1 mg/kg 3X/week), anti-PD1/Nivolumab (5 mg/kg ip q5d) or the combination was initiated after documentation of tumor engraftment (n = 5/group) Tumor burden, median survival (MS) were recorded. T-cell numbers/phenotype and drug PD were measured in blood and tumors. Results: Consistent with the pharmacologic rationale, THU-Dec/5Aza produced > 2-fold more DNMT1-depletion in tumor, and > 2-fold extension of MS, vs Dec or 5Aza alone. THU-Dec/5Aza or anti-PD1 alone increased MS vs PBS (THU-Dec/5Aza 60 d, anti-PD1 64 d, PBS 40 d), but strikingly, the combination produced cures. Immune-augmentation was demonstrated by > 5-fold increase in tumor infiltrating lymphocytes (TILs) with the combination vs PBS. An immune-basis for cures was confirmed by LL3-luc rechallenge, which did not engraft in surviving mice, but engrafted treatment naïve mice. Extending these results, in the humanized PDX, the combination again produced the greatest tumor regression (PBS 2.06 g, THU-Dec/5Aza 0.39 g, Nivolumab 0.54 g, combination 0.21 g). Again, TILs were increased ~5-fold with the combination vs PBS (p < 0.01). Also noted were significantly higher IFNγ, granzyme B, perforin expression in tumor 3.8, 4.2, 3.6-fold respectively vs PBS (p < 0.01). Conclusions: Combining THU with alternating Dec/5Aza realizes the value of DNMT1 as a molecular target that increases immune-recognition and destruction of NSCLC in vivo, scientific validation of our trial NCT02664181.

The Topoisomerase I Inhibitor Irinotecan And The Tyrosyl-Dna Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis

The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl‐DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis

Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan

Low‐Dose Irinotecan Improves Advanced Lupus Nephritis in Mice Potentially by Changing DNA Relaxation and Anti–Double‐Stranded DNA Binding

Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis

Novel Mitophagy Inducer Alleviates Lupus Nephritis by Reducing Myeloid Cell Activation and Autoantigen Presentation.

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

A Small-Molecule Macrophage Migration Inhibitory Factor Antagonist Protects Against Glomerulonephritis in Lupus-Prone NZB/NZW F1 and MRL/lpr Mice.

DNA Nanoflowers’ Amelioration of Lupus Symptoms in Mice via Blockade of TLR7/9’s Signal

Design, Synthesis, Mechanisms of Action, and Toxicity of Novel 20(S)-Sulfonylamidine Derivatives of Camptothecin As Potent Antitumor Agents

Distinct Effects of Mycophenolate Mofetil and Cyclophosphamide on Renal Fibrosis in NZBWF1/J Mice

Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus

Norcantharidin ameliorates the development of murine lupus via inhibiting the generation of IL-17 producing cells

The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo

Tetrahydrouridine/decitabine/5-azacytidine for Non-Cytotoxic Epigenetic-Immunotherapy of NSCLC in Vivo.

DNA Repair and Resistance to Topoisomerase I Inhibitors: Mechanisms, Biomarkers and Therapeutic Targets

Novel Small Molecule Inhibitors of TLR7 and TLR9: Mechanism of Action and Efficacy In Vivo

Potential Small Molecules for Therapy of Lupus Nephritis Based on Genetic Effect and Immune Infiltration

Enhancement of the Antitumor and Antimetastatic Effect of Topotecan and Normalization of Blood Counts in Mice with Lewis Carcinoma by Tdp1 Inhibitors—New Usnic Acid Derivatives

The Effect of Targeted Delivery of Anti-Tnf-α Oligonucleotide into CD169+ Macrophages on Disease Progression in Lupus-Prone MRL/lpr Mice.

Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus